Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04346225 · ClinicalTrials.gov registry record · Phase 2
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
A Phase 2 study of Prostate Cancer and Advanced Prostate Carcinoma, sponsored by Ivan de Kouchkovsky, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT04346225 is a Phase 2 study of Prostate Cancer and Advanced Prostate Carcinoma that is actively recruiting participants, run by Ivan de Kouchkovsky, MD. The registered enrollment target is 75 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04346225, a Phase 2 study of Prostate Cancer and Advanced Prostate Carcinoma, is actively recruiting participants, sponsored by Ivan de Kouchkovsky, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a diagnostic and response monitoring tool in patients with advanced prostate cancer. Preliminary pre-clinical and clinical data demonstrates the ability of HP C-13 pyruvate/metabolic MR imaging to detect high-grade prostate cancer, including cancer with neuroendocrine differentiation, as well as provide early evidence of metabolic response and resistance following application of systemic therapies for the treatment of advanced prostate cancer patients. In the proposed study, the investigators aim is to extend the initial clinical results and further develop HP C-13 MRI as an imaging modality in advanced prostate cancer.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- DRUG Hyperpolarized C13
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04346225
The ClinicalTrials.gov registry entry for NCT04346225 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Ivan de Kouchkovsky, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT04346225 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04346225 about?
NCT04346225 is a clinical study titled "Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer". This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a diagnostic and response monitoring tool in patients with advanced prostate cancer. Preliminary pre-clinical and clinical data demonstrates the ability of HP C-13 pyruvate/metabolic MR imaging to detect h...
What is the current status of trial NCT04346225?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2020-07-16. Estimated completion is 2026-11-30.
What conditions does trial NCT04346225 study?
This clinical trial studies the following conditions: Prostate Cancer, Advanced Prostate Carcinoma.
What interventions are being tested in trial NCT04346225?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Hyperpolarized C13 (DRUG).
Who is sponsoring clinical trial NCT04346225?
This trial is sponsored by Ivan de Kouchkovsky, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04346225 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.